The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $155.72

Today's change+4.23 +2.79%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $155.72

Today's change+4.23 +2.79%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc up sharply

Intercept Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$4.23 or 2.79% to (U.S.)$155.72. Shares have lost 0.58% over the last five days, but have gained 128.06% over the last year to date. This security has outperformed the S&P 500 by 121.58% during the last year.

Key company metrics

  • Open(U.S.) $150.00
  • Previous close(U.S.) $151.49
  • High(U.S.) $156.21
  • Low(U.S.) $150.00
  • Bid / Ask-- / --
  • YTD % change+128.06%
  • Volume182,722
  • Average volume (10-day)554,694
  • Average volume (1-month)539,082
  • Average volume (3-month)577,758
  • 52-week range(U.S.) $65.10 to (U.S.) $497.00
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEG2.64×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$12.76
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense37232014
Selling / general / administrative9865
Research & development27151410
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-36-22-20-14
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-3633-246-12
Income after tax-3633-246-12
Income tax, total--000
Net income-3633-246-12
Total adjustments to net income------0
Net income before extra. items-3633-246-12
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-3633-246-12
Inc. avail. to common incl. extra. items-3633-246-12
Diluted net income-3633-246-12
Dilution adjustment------0
Diluted weighted average shares21222119
Diluted EPS excluding extraordinary itemsvalue per share-1.691.51-11.94-0.64
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.691.51-11.94-0.64